See more : Medlive Technology Co., Ltd. (2192.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Adagene Inc. (ADAG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Adagene Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Water Technologies International, Inc. (WTII) Income Statement Analysis – Financial Results
- Kangji Medical Holdings Limited (9997.HK) Income Statement Analysis – Financial Results
- Imvest S.p.A. (YIV.MI) Income Statement Analysis – Financial Results
- Upbound Group, Inc. (UPBD) Income Statement Analysis – Financial Results
- Matsa Resources Limited (MAT.AX) Income Statement Analysis – Financial Results
Adagene Inc. (ADAG)
About Adagene Inc.
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 18.11M | 9.29M | 10.18M | 480.00K | 480.00K | 1.51M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 36.64M | 81.34M | 68.10M | 16.21M | 16.21M | 16.08M |
| General & Administrative | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 8.67M | 11.87M | 14.44M | 3.44M | 3.44M | 2.77M |
| Other Expenses | -3.48M | 2.17M | 1.78M | 723.48K | 723.48K | 901.71K |
| Operating Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Cost & Expenses | 41.83M | 93.21M | 82.54M | 19.65M | 19.65M | 18.85M |
| Interest Income | 4.28M | 377.50K | 76.17K | 922.68K | 922.68K | 710.71K |
| Interest Expense | 1.11M | 693.32K | 363.76K | 138.10K | 138.10K | 91.09K |
| Depreciation & Amortization | 1.21M | 1.43M | 1.13M | 858.41K | 816.69K | 909.00K |
| EBITDA | -14.95M | -77.39M | -69.99M | -41.34M | -15.48M | -14.27M |
| EBITDA Ratio | -82.55% | -875.68% | -692.95% | -3,650.73% | -3,480.59% | -980.24% |
| Operating Income | -23.72M | -83.92M | -72.36M | -19.17M | -19.17M | -17.33M |
| Operating Income Ratio | -130.97% | -903.08% | -711.18% | -3,993.68% | -3,993.68% | -1,147.09% |
| Total Other Income/Expenses | 6.46M | 4.41M | 887.77K | 754.38K | 2.74M | 2.07M |
| Income Before Tax | -17.25M | -79.51M | -71.48M | -16.43M | -16.43M | -15.27M |
| Income Before Tax Ratio | -95.27% | -855.65% | -702.45% | -3,423.40% | -3,423.40% | -1,010.22% |
| Income Tax Expense | 1.69M | 459.06K | 1.70M | 3.16K | 861.57K | -547.00K |
| Net Income | -18.95M | -79.97M | -73.18M | -16.44M | -17.29M | -14.72M |
| Net Income Ratio | -104.61% | -860.59% | -719.18% | -3,424.06% | -3,602.89% | -974.03% |
| EPS | -0.44 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| EPS Diluted | -0.43 | -1.85 | -1.83 | -0.47 | -0.39 | -0.43 |
| Weighted Avg Shares Out | 43.31M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
| Weighted Avg Shares Out (Dil) | 43.79M | 43.31M | 40.03M | 35.08M | 44.17M | 34.41M |
Adagene (ADAG) Stock: Why The Price Increased Today
Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates
Adagene Inks Third Cancer Trial Collaboration With Merck
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
Adagene To Test Its Anti-CTLA-4 Monoclonal Antibodies In Combination With Keytruda In Solid Tumors
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
Adagene Announces Inclusion in FTSE Russell Indexes
Source: https://incomestatements.info
Category: Stock Reports